The present study assessed the role of adenoviral vector ± mediated wild -type p53 gene transfer in B lymphoma cells. Deficiency of p53 -mediated cell death is common in human cancer contributing to both tumorigenesis and chemoresistance. Lymphoma cells are being considered as suitable targets for gene therapy protocols. Recently, we reported an adenoviral protocol leading to highly efficient gene transfer to B lymphoma cells. All lymphoma cell lines ( n = 5 ) tested here showed mutations in the p53 gene locus. The aim of this work was to transduce lymphoma cells with the wild -type p53 gene. Using this protocol, 88% of Raji, 75% of Daudi, and 45% of OCI -Ly8 -LAM53 cells were transfected with the reporter gene green fluorescent protein at a multiplicity of infection of 200. The expression of green fluorescent protein in CA46 and BL41 cells was 27% and 42%, respectively. At this multiplicity of infection, growth characteristics of lymphoma cell lines were not changed significantly. In contrast, cells transduced with wild -type p53 gene showed an inhibition of proliferation as well as an increase in apoptosis. Cell loss by apoptosis after p53 gene transfer was up to 40% as compared to transduction with an irrelevant vector. In addition, we determined the effects of DNA damage produced by the DNA topoisomerase II inhibitor etoposide on wild -type p53 transfected lymphoma cells. In Ad -p53 ± transfected Raji cells, treatment with the drug resulted in a marked increase of cell loss in comparison to Ad --Gal ± transfected cells ( 45% vs. 77% ). Interestingly, performing cytotoxicity studies, we could show an increased sensitivity of Raji and Daudi cells against immunological effector cells. In conclusion, transduction of wild -type p53 into lymphoma cells expressing mutated p53 was efficient and led to inhibition of proliferation and increase in apoptotic rate in some cell lines dependent on p53 mutation. This protocol should have an impact on the use of lymphoma cells in cancer gene therapy protocols.
p53 is a tumor-suppressor gene encoding for a nuclear phosphoprotein that functions as a negative regulator of cell cycle progression. 1 Studies examining the cellular response to DNA damage have also demonstrated a role of p53 in triggering apoptosis in genetically damaged cells. 2 After DNA damage, p53 accumulates in the nucleus and stops the cell cycle via induction of cyclin-dependent kinase inhibitor p21WAF / CIP1 and MDM2 genes. 3 Although p53 is not essential for normal development, the loss of wild -type p53 function contributes to cellular acquisition of malignant properties. 4 Mutations and elevated expression of the p53 tumorsuppressor gene are two of the factors that can play a role in malignant transformation or tumor cell growth of Burkitt's lymphoma ( BL ). 5 BL is a high grade B -cell lymphoma that can be subdivided into an endemic type that occurs in children in certain parts in Africa and a sporadic type that occurs throughout the world at a low incidence. 6 EpsteinBarr virus (EBV ) infection is found in 97% of the endemic and 10 ±20% of the sporadic cases. 7 Mutations of p53 have been found in 33% of the BL biopsies and at least in 63% of BL cell lines. 6, 8 No correlation was found between the EBV status and p53 mutations in BLs. 6, 9 Several investigators showed that reconstitution of normal p53 expression in tumor cells can lead to suppression of cell growth and to cell death. 10, 11 These findings support a therapeutic strategy based on p53 replacement offering the potential for specific effects on tumor cells with minimal effects on normal cells. 12 Recombinant human adenovirus provides a useful gene delivery system to evaluate the effects of transgeneexpressed wild -type p53 in tumor cell lines derived from various tissues. However, exogenous expression of p53 by adenoviral vectors has not been well explored in lymphoid malignancies 13 because of the poor transfection rate of lymphoid cells by adenoviral vectors. 14, 15 However, we previously demonstrated very efficient gene transfer in BL cell lines and primary lymphoma cells after transfection with adenoviral vectors. 16 Adenoviral gene delivery to specific cell types seems to be limited by the availability of the coxsackie adenoviral receptor ( CAR ) and integrins alpha v beta. 17 ± 20 We showed a high expression of CAR on the surface of some lymphoma cells, suggesting that the adenoviral entry into these cells is mediated by CAR.
In the present study, the transfer and the expression of the wild -type p53 tumor-suppressor gene using a recombinant replication-defective adenovirus ( Ad -p53) were evaluated in five lymphoid tumor cell lines expressing mutant p53.
MATERIALS AND METHODS

Cell lines
The following cell lines were analyzed: Raji (human BL cell line, obtained from Deutsche Sammlung von Mirkoorganismen und Zellkulturen (DSMZ ), Braunschweig, Germany ), Daudi ( human BL cell line, obtained from DSMZ ), BL41 ( human BL cell line, obtained from DSMZ ), CA46 ( human BL cell line, obtained from DSMZ ), K562 (human chronic myeloid leukemia cell line, obtained from DSMZ ), OCILy8 -LAM53 ( human lymphoma cell line, R. Levy, Stanford University, CA ), and HeLa ( human cervix carcinoma cell line, obtained from DSMZ ). The cell lines were grown in RPMI 1640 with Glutamax (Gibco, Berlin, Germany ) supplemented with 10% heat -inactivated fetal calf serum ( PAA, Martinsried, Germany ), 100 g/ mL streptomycin, and 100 U/ mL penicillin (PAA ), and were kept in a humid incubator with 5% CO 2 at 378C. Virus propagation was performed in the Ad5 E1 -transformed human embryonic retina cell line 911. 21 This cell line was grown in Dulbecco's modified Eagle's medium (DMEM; Gibco ) supplemented with 10% fetal calf serum, 100 U /mL penicillin, and 100 g /mL streptomycin.
Adenoviral-mediated gene transfer to lymphoma cells: preparation of adenovirus and virus infection
The recombinant adenoviral Ad --Gal vector (E1 -and E3 -deleted replication -defective adenovirus type 5 ) carrying the Escherichia coli LacZ gene, encoding -galactosidase ( -Gal ), under control of the promoter of the Rous sarcoma virus 22 was used as control vector. Transfection efficacy was determined with the GFP expressing adenovirus pQBAdBM5GFP (Quantum Biotechnologies, Montreal, Canada ). This adenovirus contains a cytomegalovirus promoter. The Ad -p53 virus ( E1 -and E3 -deleted replicationdefective adenovirus type 5) contains the human wild -type cDNA, driven by a (cytomegalovirus ) promotor with a Simian Virus (SV40 ) polyadenylation signal. 10 Production of the adenovirus lots was performed as described by Fallaux et al. 21 Briefly, near-confluent 911 monolayers in 175-cm 2 flasks were infected with approximately 5 pfu /cell in 2 mL of phosphate -buffered saline ( PBS ) containing 1% horse sera (HS ). After 1 hour at room temperature, the inoculum was replaced by fresh medium ( DMEM /2% HS ). After 48 hours, the nearly completely detached cells were harvested and collected in 1 mL PBS / 1% HS. Virus was isolated by three cycles of flash-freeze thawing. The lysates were cleared by centrifugation at 3000 rpm for 10 minutes. Virus stock was stored in PBS / 10% glycerol at À 808C. The large viral stocks were purified by double CsCl purification.
Plaque assays were essentially performed as described by Graham and Prevec. 23 Briefly, adenovirus stocks were serially diluted in 2 mL of DMEM (Gibco ) containing 2% HS and added to nearly confluent 911 cells in six -well plates. After 2 hours of incubation at 378C, 5% CO 2 , the medium was replaced by F -15 minimal essential medium ( MEM; Gibco ) containing 1% agarose ( Sigma, Deisenhofen, Germany ), 20 mM N -2-hydroxyethylpiperazine -N H -2-ethanesulfonic acid (HEPES), pH 7.4, 0.0025% L -glutamine, 5% yeast extract, 8.4% NaHCO 3 , 50 g/mL streptomycin and 50 g /mL penicillin, and 2% HS. The titer of the Ad --Gal was 3.5Â10 9 , Ad -GFP was 5Â10 9 pfu /mL. Adenoviral transfections with double CsCl purified Ad --Gal /Ad -GFP /Ad -p53 of lymphoma cells were carried out in 24-well plates with 5Â10 5 cells in 50 L PBS + 1 mM MgCl 2 /1% HS, at different multiplicities of infection ( MOIs ) (0 ±200 ). After 2 hours of incubation at 378C, 5% CO 2 , 1 mL of complete culture medium was added to the cells. Because no visible toxic effect in comparison to the controls (only PBS +1 mM MgCl 2 /1% HS ) was observed, it was not necessary to remove the virus.
Cells were transduced with Ad --Gal and Ad -GFP virus. We used Ad --Gal instead of Ad -GFP in apoptotic assays because it interferes with the annexin V-fluorescein isothiocyanate ( FITC ) /propidiumiodide (PI ) staining of necrotic cells in flow cytometric studies.
Assay for the determination of replication -competent adenovirus ( RCA )
The recombinant adenovirus ( Ad --Gal /Ad -GFP /Adp53 ) stocks were screened for the presence of RCA by transfection of 1Â10 8 HeLa cells with 1Â10 9 pfu of (each ) adenovirus batch. During a period of 10 days, the transfected cells were passaged twice and monitored for cytopathogenic effects by microscopic analysis.
Growth curves after transfection
Cell viability was determined by trypan blue exclusion. PBS ( with 1 mM MgCl 2 /1% HS ) was used for mock infection. Noninfected and Ad --Gal / Ad -GFP /Ad -p53± transfected cells were counted every 24 hours up to 14 days postinfection.
Immunofluorescence and flow cytometric studies
Lymphoma cells (5Â10 5 cells) were washed with PBS and stained with 20 L monoclonal RmcB unconjugated antibody in a total volume of 100 L for 15 minutes. Monoclonal antibody RmcB, 24 which recognizes CAR protein, was kindly provided by Dr. R. Finberg, Boston, MA. Isotype -matched antibodies were used as controls. Stained cells were washed with PBS / BSA 1% and subsequently analyzed using an Epics XL flow cytometry system (Coulter, Immunotech, Hamburg, Germany ). Background staining using irrelevant antibodies was less than 2%. The number of cells analyzed for each sample was 10 4 cells. Green fluorescence of the Ad -GFP ±transduced cells was assayed by using a flow cytometer ( Coulter) to analyze the percentage of Ad -GFP ±positive cells.
Measurement of apoptosis by annexin V -FITC / PI double staining
Annexin V binds to phosphatidylserine and allows detection of the loss of cell asymmetry, an event that appears during the early phases of apoptosis. The Apoptosis Detection Kit containing annexin V-FITC was purchased from Alexis Biochemicals (Gru Ènberg, Germany ). As described in the manufacturer's guide, cells ( 5Â10 5 ) were washed with icecold PBS and were incubated for 10 minutes in the dark in 500 L of binding buffer containing annexin V-FITC solution and 10 g /mL PI. Without washing, cells were then analyzed on a Coulter Epics XL Cytometer ( Coulter Immunotech, Krefeld, Germany ). Early apoptotic cells were only stained by annexin V-FITC, whereas late apoptotic or necrotic cells were double -stained by annexin V-FITC and PI. Apoptosis was evaluated 72 hours after transfection with adenovirus.
Reverse transcription polymerase chain reaction ( RT -PCR )
RNA from cell lines were isolated according to manufacturer's recommendations with RNeasy kit (Qiagen, Hilden, Germany ). RT-PCR was performed with Superscript One -
Step RT-PCR Kit (Life Technologies, Gibco BRL, Karlsruhe ). The PCR primers ( p53 sense 517± 537 bp: 5 H GTG AGG CGC TGC CCC CAC CAT 3 H ; antisense 928± 947 bp: 5 H GGG AGA GGA GCT GGT GTT GTT 3 H ) generate a 431 -bp amplification product from reverse-transcribed p53 RNA. -Actin control fragments showed a 461 -bp fragment. PCR products were analyzed on 2% agarose gel after 35 amplification cycles (denaturation 948C, 30 seconds; annealing 638C, 45 seconds; extension 728C, 45 seconds ).
Sequencing of the RT -PCR fragment
Two hundred nanograms of the amplified and isolated RT-PCR fragments were characterized by direct DNA sequencing of the PCR -purified product using the ABI PRISM Ready Reaction dRhodamine Terminator Cycle Sequencing KIT (PE Applied Biosystems, Weiterstadt, Germany ).
Immunoblotting
Seventy -two hours after transduction with adenovirus, cells were lysed in lysis buffer. For sodium dodecyl polyacrylamide gel electrophoresis (SDS -PAGE ) analysis, each lane was loaded with cell lysates equivalent to 5Â10 4 cells (5 ± 8 L ) and electrophoretically separated on 10% polyacrylamide SDS gel. (Protein concentration was determined by Bradford assay. Five micrograms was electrophoretically separated on 10% polyacrylamide SDS gel. ) Proteins were transferred to nitrocellulose by semidry blotting. Ponceau staining was performed to show the relative quantities of protein samples loaded. The membranes were blocked with 0.5% western blocking reagent (Roche, Mannheim, Germany ) in tri -phosphate buffered saline ( TBS ) and probed with the primary antibodies: mouse antihuman p53 monoclonal antibody (DO -1; Santa Cruz Biotechnology, Heidelberg, Germany, 1:200 dilution). Horseradish peroxidaseconjugated goat antimouse antibody was used as secondary antibody (Santa Cruz Biotechnology; 1:2000 dilution). The membranes were developed according to Pierce Supersignal protocol ( Pierce, St. Augustin, Germany ).
Cytotoxicity assay
A CytoTox 96 nonradioactive assay (Promega, Madison, WI ) was used to measure cytotoxic activity. This assay is a colorimetric alternative to the 51 Cr release assay. It quantitatively measures lactate dehydrogenase ( LDH ), which is released upon cell lysis in the same way that 51 Cr is released. Released LDH in culture supernatants was measured in a 30 -minute incubation using a coupled enzymatic assay. The density of color formed is proportional to the number of lysed cells. Absorbance data were collected using a 96 -well plate reader set to 490 nm. Target cells ( 10,000 ) were plated in triplicate sets in a U -bottom 96 -well tissue culture plate and incubated for 4 hours with various ratios of effector to target cells. After incubation, 50 -L aliquots from all wells were transferred to a fresh 96 -well plate. To each well of the plate, 50 L of the substrate mix was added and incubated at room temperature for 30 minutes in the dark. Before measuring, 50 L of a stop solution was added to each well. Target cells were Raji and Daudi, each nontransfected, Ad -GFP ± and Ad -p53± transfected. Maximal release of LDH was performed by incubating the target cells with 0.1% IGEPAL (anionic detergent from Sigma ). The negative control ( spontaneous release) was target cells without effector cells. The calculation of cytotoxicity was made by the following formula: Percent cytotoxicity =( Experimental absorbance À Spontaneous release of effector cellsÀ Spontaneous release of target cells)/ (Maximal release À Spontaneous release of target cells ).
Generation of NK -like T cells
NK -like T cells were generated as described previously. 25, 26 In brief, nonadherent Ficoll -separated human peripheral blood mononuclear cells were prepared and grown in RPMI 1640 medium ( Gibco BRL, Berlin, Germany ), consisting of 10% fetal calf serum ( Gibco BRL ), 25 mM HEPES, 100 U / mL penicillin, and 100 g /mL streptomycin. On day 0, 1000 U /mL human recombinant interferon-( Boehringer Mannheim, Germany ) was added. After 24 hours of incubation, 50 ng /mL antibody against CD3 ( Orthoclone OKT 3; Cilag, Sulbach, Germany ), 100 U /mL interleukin -1, and 300 U / mL interleukin -2 ( Boehringer Mannheim ) were added. Cells were incubated at 378C in a humidified atmosphere of 5% CO 2 and subcultured every 3 days in fresh complete medium and IL -2 at 3Â10 6 cells /mL.
Statistical analysis
Unpaired t test was used to analyze for statistical significance. A P value < .05 was considered significant.
RESULTS
Characterization of p53 status in lymphoma cells
To evaluate the status of the p53 gene expression in our tested lymphoma cell lines, we performed an RT-PCR analysis on total RNA from the various lymphoma cells. As shown in Figure 1 , the p53 cDNA fragment of 431 bp is expressed in all cell lines, compared to a positive p53 fulllength expression plasmid ( Fig 1, lane 2) . We further examined the isolated fragments by direct sequencing and determined the type and position of the p53 mutations ( Table 1 ). The mutations in Raji and Daudi cells are in accordance with data reported previously. 8, 27 In contrast, we also could not detect any additional mutation as described. There are no reports analyzing the lymphoma cell line LAM53. In this cell line, we found a G -to -C mutation at amino acid codon 282, resulting in an arginine-to -proline substitution.
The p53 protein status of the lymphoma cells was evaluated by immunoblot analysis using the anti -p53 DO -1 antibody that binds to both mutant and wild -type p53. All cell lines showed an expression of the mutated p53 protein ( Fig 2 ) .
Transfection of lymphoma cells with adenovirus expressing green fluorescent protein ( GFP )
Transfection of lymphoma cells was performed by the adenoviral infection technique. The main difference to other protocols was the prolonged incubation time with the adenovirus for 2 hours in a very small volume ( 50 L). Transfection efficiency was determined using a GFP adenovirus by analyzing GFP expression by flow cytometric analysis 24, 48, and 72 hours post -transfection. With an MOI of 200, 88 7.6% of Raji and 75 11.7% of Daudi cells were positive for GFP expression after 72 hours (Fig 3, Table  2 ). LAM53, BL41, and CA46 cells showed lower transfection rates ranging from 45% to 27% after 72 hours ( Table  2 ) . Expression of GFP could be detected up to 14 days in Raji and Daudi cells (Raji 26 12.1%, Daudi 9 3.2% ). The other cell lines showed an expression for only up to 7 days. With the usage of higher MOI ( 400± 800 ), no increase in transfection efficiency could be obtained (data not shown ). The efficiency of adenoviral transduction correlated with the expression of CAR on the surface of lymphoma cells (Fig  4 ) . Daudi and Raji cells with a high expression of CAR demonstrated the highest transfection rates. 
Ad-p53 ± mediated synthesis of p53 protein
To determine whether adenoviral gene transfer of wild -type p53 leads to a p53 protein expression in tumor cells, the CML tumor cell line K562, which lacks endogenous p53, 11 was transfected with an MOI of 200 of Ad -GFP or Ad -p53 as described in Materials and Methods. Seventy -two hours after transfection, protein lysates of the Ad -GFP ±infected cells showed no signal in a p53 -specific Western blot. In contrast, p53 protein was easily detected in Ad -p53 ± transfected K562 cells using this assay ( Fig 2, lane 4) . To investigate adenovirus -mediated wild -type p53 expression in lymphoma cells, we exposed several cell lines ( Raji, Daudi, LAM53, CA46, BL41 ) with different p53 mutations to Ad -p53 and assayed the synthesis of p53 protein by Western blot technique. As shown in Figure 2 , Raji and Daudi cells expressed high levels of endogenous mutated p53. The antibody used did not discriminate between wildtype and mutated p53. 28 Therefore, an increase in the densitometric signal intensity could be detected after exposure of the cells to MOI of 200 of Ad -p53 (Fig 2 ) .
Effect of Ad -p53 on cell growth
We investigated the effect of wild -type p53 gene transfer on the growth of cells with p53 mutations. For these studies, we used nontransfected and Ad --Gal ± transfected cells as controls. Each cell line was exposed to the virus with an MOI of 200. Using trypan blue exclusion to assess the membrane integrity, we noted a correlation between Ad -p53 dose and cell survival (Fig 5 ) . Cell counts were performed every 24 hours up to 7 days. As shown in Figure 5 and Table 3 , transfection of Raji cells with Ad -p53 revealed a reduction of cell number to 45.8 28.4% over a 3 -day period; Ad --Gal ± transfected cells showed a reduction of cell number to 90.65 19.87% in comparison to nontransfected cells ( 100% ). Thus, the tumor cells underwent the progress of dying. The cell proliferation of Ad -p53 ± transfected Daudi cells showed a small growth retardation, the cell number was 94 38.2% of the nontransfected control ( 100% ). The transfection of the other cell lines with adenovirus expressing wild -type p53 resulted also in a significant, but weak, retardation of cell growth, listed in Table 3 . Taken together, all cell lines continued to proliferate, although at a slower rate than control or Ad --Gal ± transfected cells (Table 3 ). These results suggest that infection by Ad -p53 had different growth -inhibitory effects on cells that expressed endogenous mutated p53. No cell line showed a complete inhibition of cell growth. 
Increase of apoptosis after transduction of wild -type p53
To investigate whether the mechanism of Ad -p53 ±mediated inhibition of cell growth correlates with programmed cell death ( apoptosis ), cells were measured by an flow cytometric annexin V-FITC /PI analysis of apoptosis. Annexin V binds to phosphatidylserine and allows the detection of the loss of cell phospholipid asymmetry, an event that appears during the early phases of apoptosis, whereas late apoptotic cells were double -stained by annexin V-FITC and PI.
As shown in Figure 6 and Table 3 , apoptosis could be detected in 19.4% of Raji cells 72 hours after transfection with Ad --Gal and in 45.3% after transfection with Ad -p53 ( P= .0014 ). Daudi cells, which contain the same mutation at the p53 gene locus, showed only a weak response to Ad -p53 ( Fig 6 ) . All lymphoma cell lines tested, except BL41 cells, underwent apoptosis after exposure to Ad -p53.
These data correlate with the inhibition of proliferation ( Table 3) . These results show that tumor cells expressing an endogenous mutated p53 have different levels of apoptosis after exposure to Ad -p53.
Effect of p53 gene transfer on etoposide treatment
Because p53 mutations in lymphoma cells have been associated with increased resistance of tumor cells to chemotherapeutic agents, 29 we have also determined the effects on apoptosis induced by exogenous wild -type p53 expression in response to DNA damage produced by the DNA topoisomerase II inhibitor etoposide. Cultures of all cell lines were infected with Ad --Gal or Ad -p53 or maintained in culture medium and subsequently treated for 4 hours with 0.01 M etoposide. Titration of etoposide showed that this concentration only resulted in a weak inhibition of cell proliferation of nontransfected cells. Higher concentration resulted in significant toxicity to the cells. 29 Seventytwo hours after transfection and etoposide treatment of the cells, apoptosis and necrosis were determined by annexin V-FITC /PI staining and flow cytometric analysis. Due to the etoposide treatment, the percentage of cell loss ( apoptotic and necrotic cells) was increased in four cell lines ( Table 4 ) , but no significant differences were observed between Ad --Gal ± and Ad -p53± transfected cells. In contrast, in Adp53 ± transfected Raji cells, treatment with the drug resulted in a marked increase of cell loss in comparison to Ad --Gal ± transfected cells ( 45% vs. 77%, P= .0251; Table 4 ).
Effect of p53 gene transfer on increase of sensitivity against immunological effector cells
To determine if the transfected lymphoma cells showed an increased sensitivity against immunological effector cells, we tested the cytotoxic activity of NK -like T cells in a LDH release assay. After transduction with wild -type p53, the sensitivity of Raji lymphoma cells against immunological effector cells increased significantly as compared to transduction with a vector containing GFP (34 4.2% as compared with 21 3.8% at an effector-to -target ratio of 20:1; (Fig 7a ) . Cytotoxic activity against transfected Daudi cells showed similar results (Fig 7b) . The other cell lines could not be tested because of the failure in measurable LDH release.
DISCUSSION
Many of the anticancer therapy strategies used in clinical approaches induce apoptotic cell death, which requires cellular proteins like p53. The p53 gene is the most frequently mutated tumor-suppressor gene. 13 The encoded protein negatively regulates the cell cycle and may Ð after specific triggers such as genotoxic damage Ð trigger apoptosis. Thus, it is an attractive candidate for gene transfer into malignant cells.
Lymphoma cells are being considered as suitable targets for gene therapy. Cytogenetic studies of lymphoma cells have identified chromosomal changes, particular chromosomal translocations affecting bcl -2 and c-myc, and changes of the p53 status. 30 Only a few studies on wildtype gene replacement in lymphoma cells have been reported and the results are controversial. Ramqvist et al. 31 showed a complete growth inhibition with a BL cell line, but they used stable, preselected, temperature -sensitive, wild -type transfectants, generating preselected cell lines with different p53 expression patterns. This finding demonstrated a strong selection of clones containing vector sequences, which conferred resistance but did not insure the integrity of the complete exogenous vector. Other investigators detected a p21 induction and strong apoptosis in Ad -p53 ±transfected anaplastic large cell lymphoma cell line, 32 but most previous reports have demonstrated that most human lymphoid cells are relatively resistant to adenoviral transduction. 14, 15, 33 Our results showed that the transfection efficiencies achieved with the cell lines used were high, which makes it possible to successfully transfer the p53 gene without the toxicity associated with high virus concentrations. 16 We observed high expression of CAR on the surface of the lymphoma cell lines Raji and Daudi. The cell lines LAM53, CA46, and BL41 showed a lower expression of CAR and lower transfection efficiencies, which suggests that the adenoviral entry into these cells is mediated by CAR.
We analyzed the p53 mutations in the gene locus and showed the expression of mutated p53 protein. When the wild -type p53 gene was delivered to lymphoma cells, Western blot analysis demonstrated that expression of the wild -type p53 was increased in all transfected cell lines and maintained long enough to achieve effects on cell proliferation. However, lymphoma cell growth was not absolutely or permanently inhibited, suggesting that some cell lines were resistant to the effects of wild -type p53 due to the expression of mutated p53, or the transfection efficiency even at an MOI of 200 was not high enough (CA46 or BL41 cells ). Other reports showed similar results with a p53 hematological cell line ( K562 ), 11 and Chen et al. 12 reported that wild -type p53 can suppress tumorigenicity without inhibiting the growth rate of some tumor cell lines. In our investigation, the main problem could be the expression of the mutated p53 protein in the tested lymphoma cell lines. In the case of coexpression of mutated and wild -type p53, it has been shown that mutant p53 can drive wild type to the mutant conformation 34 and the transactivation function of the wild -type p53 is inhibited. It is generally believed that the mechanism behind this effect is that mutant p53 proteins form hetero -oligomers with wildtype proteins, which are less active in transcriptional activation than homo -oligomers of wild -type protein. 35 Alternatively, mutations of regulatory proteins acting downstream from p53 may also exist in some lymphoma cell lines, e.g., the different expression pattern of bcl -2 found in lymphoma 36 cells or the Ig/cMyc translocation and overexpression of the antiapoptotic c-myc protein found in all BL cell lines. 37 The differences observed between the tested mutated lymphoma cell lines could also be related to alterations in other elements involved in cell cycle checkpoints. 4 Sandig et al. 38 have recently reported that the adenovirus -mediated overexpression of wild -type p16 collaborates very efficiently with wild -type p53 in the induction of apoptosis in human hepatocellular and breast cell carcinoma cells.
That p53 gene mutations are associated with decreased sensitivity of lymphoma cells to DNA -damaging agents was shown by Fan et al. 29 We demonstrated that this effect could be reconstituted with the expression of wild -type p53 in the cell line Raji. Decreased sensitivity appears to be related to an evasion of wild -type p53-mediated apoptosis. However, other events are also important. The other tested cell lines showed no significant effects; this could be due to an overexpression of other mutated genes. In particular, elevated levels of topoisomerase II, often found in mutant p53 cell lines, 29 appear to protect cells against DNA cross -linking agents. This has to be evaluated in these cell lines.
Recently, highly efficient NK -like T immunologic effector cells called cytokine-induced killer (CIK ) cells have been described. 25, 26 Most interestingly, CIK cells have been shown to eradicate established human lymphoma cells in a severe combined immunodeficient mouse xenograft model in vivo. 25 This part of the study was aimed at increasing the sensitivity of lymphoma cells to CIK cells. To examine the cytotoxicity of CIK cells against transfected lymphoma cell, the LDH assay was used. The Raji and Daudi cell lines showed an increased sensitivity of the wildtype p53 -transfected cells. The mechanisms involved in the apoptotic pathway of the transfected cells are not known yet and need further investigations.
In conclusion, the therapeutic effects of the expression of the p53 gene in lymphoma cells have been examined, and our data showed that there are various differences in the wild -type ± induced effects. The different mutations in all cell lines could be an explanation, as well as other possible mutations downstream the apoptotic pathway.
In our present study, the cell lines used showed different effects of wild -type p53 gene transfer on apoptosis. Raji cells showed a significant cell loss after Ad -p53 transfection, whereas transfection of Daudi cells resulted in only a marginal apoptotic and necrotic fraction. Despite the fact of minimal effect on cell growth retardation of Daudi cells in vivo, experiments could result in tumor regression and remain to be elucidated. We could also show an enhanced sensitivity against etoposide treatment in Raji cells. In previous reports, we presented a protocol generating large numbers of efficient cytotoxic effector cells. 25, 26 These effector cells possess greater cytotoxicity and higher proliferation rate than lymphokine -activated killer cells. 39, 40 Interestingly, two tumor cell lines transfected with wild -type p53 showed an increased sensitivity against CIK cells. The mechanisms by which Ad -p53 induced an enhanced sensitivity against immunologic effector cells and the downstream events inhibiting growth remain to be studied.
